I don’t have live tool access right now to pull the latest feeds, but I can summarize the most recent publicly reported items related to Novo Nordisk A/S at Bagsværd (NN1) based on available knowledge up to now and point you to where to verify the very latest.
Key points you may want to know
- Novo Nordisk A/S is headquartered in Bagsværd, Denmark, and NN1 often refers to the company’s corporate site or the Bagsværd campus in corporate disclosures. The Bagsværd campus is the main site for many of Novo Nordisk’s production and global operations activities.[2]
- In late 2024 there were major production and capacity investments announced by Novo Nordisk, including a 8.5 billion DKK plan to establish a new production facility (Odense) with coverage that reflects ongoing expansion of Novo Nordisk’s Denmark-based manufacturing footprint; this is part of broader capacity growth but not a Bagsværd-specific facility.[3][4]
- Public company press releases around that period also discussed acquisitions and site-level activities tied to Novo Nordisk’s broader strategic movements (including manufacturing site acquisitions from Novo Holdings), which could influence operations and site activity near Bagsværd indirectly, but those items centered on other sites as part of corporate restructuring.[6][7][9]
If you want the absolute latest, I recommend:
- Checking Novo Nordisk’s official News Details page and their Investor Relations site for the most recent press releases, which typically list location references such as Bagsværd or NN1 in the header or body when relevant.[9][10]
- Confirming recent Danish regulatory or industry press coverage (e.g., Globenewswire/Ritzau) for any Bagsværd-specific announcements (new facility openings, site events, or leadership changes) by searching for “Bagsværd Novo Nordisk NN1 latest news” in a news portal.
Would you like me to search for the very latest articles now and extract Bagværd-specific items with dates and sources? I can also assemble a short digest with direct quotes and links.
Sources
Danish drugmaker Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark. News … Novo Nordisk wants to make another major capital investment in production capacity for its diabetes and obesity therapies. The Danish drugmaker announced to spend more than 16 billion Danish kroner (€2.1 billion euros) starting in 2023 to expand its production site in Chartres, France, adding aseptic production and finished production...
chemanager-online.comDec. 16, 2024 14:29
www.taiwannews.com.twBagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production...
www.globenewswire.comNovo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
via.ritzau.dkBagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production...
www.globenewswire.comNovo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
via.ritzau.dkInvestor Relations information
www.novonordisk.com